Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature
Descripción del Articulo
We are currently in a global pandemic caused by the coronavirus 2019 or COVID-19, presenting different challenges for the health system due to the fact that there is still no vaccine or a treatment that has proven its effectiveness in its entirety, being the management current preventive and support...
| Autores: | , , |
|---|---|
| Formato: | artículo |
| Fecha de Publicación: | 2021 |
| Institución: | Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| Repositorio: | Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| Lenguaje: | español |
| OAI Identifier: | oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/821 |
| Enlace del recurso: | https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/821 |
| Nivel de acceso: | acceso abierto |
| Materia: | COVID–19 Hidroxicloroquina Tocilizumab Anakinra Baricitinib Agentes antirreumáticos COVID-19 hydroxychloroquine tocilizumab anakinra baricitinib antirheumatic agents |
| id |
REVCMH_5a416f4e36b32ecfccbd7fdf7fa2eef0 |
|---|---|
| oai_identifier_str |
oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/821 |
| network_acronym_str |
REVCMH |
| network_name_str |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| repository_id_str |
|
| spelling |
Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literatureUso de antirreumáticos en covid-19 desde la hidroxicloroquina hasta la anakinra pasando por tocilizumab y baricitinib: Una revisión de la literaturaSalas-Bolaños, Rosa AlejandraSevilla-Rodriguez, David EzequielArroyo-Sánchez, Abel SalvadorCOVID–19HidroxicloroquinaTocilizumabAnakinraBaricitinibAgentes antirreumáticosCOVID-19hydroxychloroquinetocilizumabanakinrabaricitinibantirheumatic agentsWe are currently in a global pandemic caused by the coronavirus 2019 or COVID-19, presenting different challenges for the health system due to the fact that there is still no vaccine or a treatment that has proven its effectiveness in its entirety, being the management current preventive and supportive. Therefore, this review will study the most prominent antirheumatic drugs that have a probable pharmacological effect, such as hydroxychloroquine, tocilizumab, anakinra and baricitinib, against COVID-19. It is expected that they will provide support for future treatments. and research on the disease.Actualmente nos encontramos en una pandemia mundial causada por el coronavirus 2019 o COVID–19, presentando diferentes desafíos para el sistema de salud debido a que no se cuenta aún con alguna vacuna ni con un tratamiento que haya demostrado su eficacia en totalidad, siendo el manejo actual preventivo y de soporte. Por lo que, en esta revisión se estudiará a los fármacos antirreumáticos más resaltantes que tengan un probable efecto farmacológico, como son la hidroxicloroquina, el tocilizumab, el anakinra y el baricitinib, frente al COVID–19. Se espera que brinde apoyo para futuros tratamientos e investigaciones sobre la enfermedad.Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo2021-04-27info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/82110.35434/rcmhnaaa.2021.141.821Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 No. 1 (2021): January - March; 52 - 63Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 Núm. 1 (2021): Enero - Marzo; 52 - 632227-47312225-5109reponame:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjoinstname:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjoinstacron:HNAAAspahttps://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/821/398Derechos de autor 2021 Rosa Alejandra Salas-Bolaños, David Ezequiel Sevilla-Rodriguez, Abel Salvador Arroyo-Sánchezinfo:eu-repo/semantics/openAccessoai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/8212022-02-01T00:21:01Z |
| dc.title.none.fl_str_mv |
Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature Uso de antirreumáticos en covid-19 desde la hidroxicloroquina hasta la anakinra pasando por tocilizumab y baricitinib: Una revisión de la literatura |
| title |
Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature |
| spellingShingle |
Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature Salas-Bolaños, Rosa Alejandra COVID–19 Hidroxicloroquina Tocilizumab Anakinra Baricitinib Agentes antirreumáticos COVID-19 hydroxychloroquine tocilizumab anakinra baricitinib antirheumatic agents |
| title_short |
Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature |
| title_full |
Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature |
| title_fullStr |
Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature |
| title_full_unstemmed |
Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature |
| title_sort |
Use of antirheumatic drugs in covid-19 from hydroxychloroquine to anakinra through tocilizumab and baricitinib: A review of the literature |
| dc.creator.none.fl_str_mv |
Salas-Bolaños, Rosa Alejandra Sevilla-Rodriguez, David Ezequiel Arroyo-Sánchez, Abel Salvador |
| author |
Salas-Bolaños, Rosa Alejandra |
| author_facet |
Salas-Bolaños, Rosa Alejandra Sevilla-Rodriguez, David Ezequiel Arroyo-Sánchez, Abel Salvador |
| author_role |
author |
| author2 |
Sevilla-Rodriguez, David Ezequiel Arroyo-Sánchez, Abel Salvador |
| author2_role |
author author |
| dc.subject.none.fl_str_mv |
COVID–19 Hidroxicloroquina Tocilizumab Anakinra Baricitinib Agentes antirreumáticos COVID-19 hydroxychloroquine tocilizumab anakinra baricitinib antirheumatic agents |
| topic |
COVID–19 Hidroxicloroquina Tocilizumab Anakinra Baricitinib Agentes antirreumáticos COVID-19 hydroxychloroquine tocilizumab anakinra baricitinib antirheumatic agents |
| description |
We are currently in a global pandemic caused by the coronavirus 2019 or COVID-19, presenting different challenges for the health system due to the fact that there is still no vaccine or a treatment that has proven its effectiveness in its entirety, being the management current preventive and supportive. Therefore, this review will study the most prominent antirheumatic drugs that have a probable pharmacological effect, such as hydroxychloroquine, tocilizumab, anakinra and baricitinib, against COVID-19. It is expected that they will provide support for future treatments. and research on the disease. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021-04-27 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/821 10.35434/rcmhnaaa.2021.141.821 |
| url |
https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/821 |
| identifier_str_mv |
10.35434/rcmhnaaa.2021.141.821 |
| dc.language.none.fl_str_mv |
spa |
| language |
spa |
| dc.relation.none.fl_str_mv |
https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/821/398 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo |
| publisher.none.fl_str_mv |
Cuerpo Médico del Hospital Nacional Almanzor Aguinaga Asenjo |
| dc.source.none.fl_str_mv |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 No. 1 (2021): January - March; 52 - 63 Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo; Vol. 14 Núm. 1 (2021): Enero - Marzo; 52 - 63 2227-4731 2225-5109 reponame:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo instname:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo instacron:HNAAA |
| instname_str |
Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| instacron_str |
HNAAA |
| institution |
HNAAA |
| reponame_str |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| collection |
Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1843263926432694272 |
| score |
12.659429 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
